High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: Case report

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Chen, Liang Yu ^a,b   Huang, Cheng Hsiung ^a,b   Kuo, Shu Chen ^a,b   Hsiao, Chen Yuan ^a   Lin, Mei Lin ^a   Wang, Fu Der ^a,b   Fung, Chang Phone ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Daptomycin nonsusceptiblefosfomycin; ICD device related endocarditis

Indexed keywords

DAPTOMYCIN; FOSFOMYCIN; LINEZOLID; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABLATION THERAPY; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CASE REPORT; DEFIBRILLATOR; DEVICE REMOVAL; DISEASE COURSE; DRUG MEGADOSE; FEMALE; FEVER; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; OUTCOME ASSESSMENT; PAROXYSMAL TACHYCARDIA; STAPHYLOCOCCUS AUREUS; SYNCOPE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PHYSIOLOGY; STAPHYLOCOCCUS INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; FEMALE; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 79957531009     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-152     Document Type: Article

References (18)

1. Moreillon P, Que YA. Infective endocarditis. Lancet 2004, 363:139-149. 10.1016/S0140-6736(03)15266-X, 14726169.
2. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001, 345:1318-1330. 10.1056/NEJMra010082, 11794152.
3. Fowler VG, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005, 293:3012-3021. 10.1001/jama.293.24.3012, 15972563.
4. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997, 40:135-136. 10.1093/jac/40.1.135, 9249217.
5. Baltz RH. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol 2009, 13:144-151. 10.1016/j.cbpa.2009.02.031, 19303806.
6. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 2007, 60:7-19. 10.1093/jac/dkm137, 17550889.
7. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665. 10.1056/NEJMoa053783, 16914701.
8. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008, 52:269-278. 10.1128/AAC.00719-07, 2223911, 17954690.
9. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008, 46:1069-1077. 10.1086/527442, 18444827.
10. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009, 34:506-515. 10.1016/j.ijantimicag.2009.08.013, 19828298.
11. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs 2009, 18:921-944. 10.1517/13543780902967624, 19548851.
12. Murchan S, Kaufmann ME, Deplano A, de Ryck R, Struelens M, Zinn CE, Fussing V, Salmenlinna S, Vuopio-Varkila J, El Solh N, et al. Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J Clin Microbiol 2003, 41:1574-1585. 10.1128/JCM.41.4.1574-1585.2003, 153895, 12682148.
13. Steed ME, Vidaillac C, Rybak MJ. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother 2010, 54:5187-5192. 10.1128/AAC.00536-10, 2981245, 20921318.
14. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (> or = 8 mg/kg) daptomycin therapy. Ann Pharmacother 2009, 43:1211-1219. 10.1345/aph.1M085, 19584384.
15. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, Wehbeh W, Urban CM, Segal-Maurer S. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009, 49:177-180. 10.1086/600039, 19500039.
16. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, Masoudi FA, Okum EJ, Wilson WR, Beerman LB, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010, 121:458-477. 10.1161/CIRCULATIONAHA.109.192665, 20048212.
17. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111:e394-434. 10.1161/CIRCULATIONAHA.105.165564, 15956145.
18. del Rio A, Anguera I, Miro JM, Mont L, Fowler VG, Azqueta M, Mestres CA. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest 2003, 124:1451-1459. 10.1378/chest.124.4.1451, 14555579.